India Remdesivir Black Market: Supply Gap May Normalize Soon, But No End To Greed
Gilead Licensees Moving To Improve Supplies
India generic remdesivir supply situation seen improving soon, with existing players Cipla and Hetero ramping up the antiviral and the arrival of new entrant Mylan. But will that be enough to control black marketing of the investigational COVID-19 therapy? The government is also keeping a close watch on the goings on.
You may also be interested in...
Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.
Which vaccines will India use for immunizing its 1.35 billion population against COVID-19? Where will the money come from? Will it allow sales of these vaccines in the market? As the world’s largest democracy gets set to roll out its immunization plan, here’s a look at a few pertinent questions.
A new cheaper version of antiviral remdesivir has been launched locally by a Indian licensee, while Chinese vaccine developers push forward with broader trials of their candidates.